In a Valneva.com press launch on 01.04.2024, the specialty vaccine firm introduced that members of its administration staff together with Thomas Lingelbach, CEO and Peter Bühler, CFO will maintain investor conferences January 8 – 10, 2024 in the course of the 42nd Annual J.P. Morgan Healthcare Convention, in San Francisco. A digital assembly may also be held on the Oddo BHF Discussion board on January 15, 2024.
Thomas Lingelbach and Peter Bühlerwill will focus on Valneva’s superior vaccine improvement pipeline which incorporates Lyme disease vaccine candidate VLA15. This Vaccine candidate is in Section 3 medical trials with full enrollment, and Valneva is partnered with Pfizer on this candidate.
For Extra Info:
The publish Valneva Investors Meetings to be Held in January 2024 appeared first on Lyme Disease Association.